The RP-HPLC method for analysis of usnic acid as potential marker of herbal drugs-based formulations containing Usnea barbata Scientific paper

Main Article Content

Vanja Tadić
Ana R. Žugić
Sofija Đorđević
Irena Žižović
Irena Homšek
Dušan Mišić
Ivana Nešić


The aim of this study was to develop and validate a sensitive RP-HPLC method for the determination of usnic acid, as a potential marker sub­stance of the herbal product for oromucosal use being a complex mixture of plant extracts and an essential oil, including the extract of Usnea barbata. Ana­lysis of usnic acid in the tested formulation was performed through an extract­ion with methanol, prior to injection onto the HPLC column (Zorbax Eclipse XDB-C18 600 Bar (4.6 mm×100 mm, 1.8 μm)). The employed gradient pro­cedure of the solvents (phosphoric acid (pH 2.5) and acetonitrile), at flow rate of 0.1 mL min-1 allowed for the efficient and reproducible separation of usnic acid from the other compounds present in the investigated complex mixture. The established suitability, linearity, precision, accuracy and selectivity/spe­cif­icity of this assay implied its applicability for the reli­able examination in the stability study of the investigated multi-ingredient herbal preparation.


Download data is not yet available.


Metrics Loading ...

Article Details

How to Cite
V. Tadić, “The RP-HPLC method for analysis of usnic acid as potential marker of herbal drugs-based formulations containing Usnea barbata: Scientific paper”, J. Serb. Chem. Soc., vol. 87, no. 9, pp. 1063–1073, Aug. 2022.
Analytical Chemistry

Funding data


S. K. Niazi, Handbook of Preformulation: Chemical, Biological and Botanical Drugs, Informa Healthcare, New York, 2007, pp. 1–11 (

Quality assurance of pharmaceuticals, A compendium of guidelines and related materials, WHO Press, Geneva, Switzerland, (assessed December 1, 2020)

Guideline on quality of herbal medicinal products/traditional herbal medicinal products (EMA/CPMP/QWP/2819/00 Rev. 2), (assessed December 1, 2020)

Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products /traditional herbal medicinal products (EMA/CPMP/QWP/2820/00 Rev. 2), (assessed June 1, 2020)

Guideline on specifications and control tests on the finished product (Eudralex 3AQ 11A) (assessed December 1, 2020)

WHO guidelines on good manufacturing practices (GMP) for herbal medicines, (assessed December 1, 2020)

I. Zizovic, D. Misic, V. Tadic, I. Arsic, S. Petrovic, S. Jovanovic, J. Ivanovic, Stamenic, J. Asanin, S. Djordjevic, A. Zugic, S. Milovanovic, D. Runjaic Antic (Faculty Of Veterinary Medicine, University Of Belgrade) WIPO (PCT) WO 2013100774 A1 (2013), (assessed December 1, 2020)

PDR for Herbal medicines, Montvale, NJ, 2004, p. 847 (

M. P. Gomez-Serranillos, C. Fernandez-Moriano, E. Gonzalez-Burgos, P. K. Divakarb, A. Crespo, RSC Adv. 4 (2014) 59017 (

K. Engel, U. Schmidt, J. Reuter, S. Weckesser, B. Simon-Haarhaus, C. M. Schempp, J. Photochem. Photobiol., B 89 (2007) 9 (

V. Popovici, L.A. Bucur, V. Schröder, D. Gherghel, C.T. Mihai, A. Caraiane, F. Ciprian, B.G. Vochița, V. Badea, Molecules 25 (2020) 1865 (

A. Sepahvand, E. Studzińska-Sroka, P. Ramak, V. Karimian, J. Ethnopharmacol. 268 (2021) 113656 (

A. Dieu, L. Mambu, Y. Champavier, V. Chaleix, V. Sol, V. Gloaguen, M. Millot, Nat. Prod. Res. 34 (2020) 3358

A. Zugic, V. Tadic, S. Savic, Pharmaceutics 12 (2020) 156 (

J-Y. Tang, K-H. Wu, Y-Y. Wang, A.A. Farooqi, H-W. Huang, S-S.F. Yuan, R-I. Jian, L-Y. Tsao, P-A. Chen, F-R. Chang, Y-B. Cheng, H-C. Hu, H-W. Chang, Antioxidants 9 (2020) 694 (

N. S. Santos-Magalhaes, N. P. S. Santos, M. C. B. Lira, M. S. Ferraz, E. C. Pereira, N. H. Silva, in Colloids in drug delivery, M. Fanun, Ed., CRC Press Taylor & Francis Group, Boca Raton, FL, 2010, p. 409 (

J. A. G. Roach, S. M. Musser, K. Morehouse, J. Y. J. Woo, J. Agric. Food Chem. 54 (2006) 2484 (

D. Cansaran, O. Atakol, M.G. Halici, A. Aksoy, Pharm. Biol. 45 (2007) 77 (

T. Kristmundsdottir, E. Jonsdottir, H. M. Ogmundsdottir, K. Ingolfsdottir, Eur. J. Pharm. Sci. 24 (2005) 539 (

R. M. Ribeiro-Costa, A. J. Alves, N. P. Santos, S.C. Nascimento, E. C. P. Goncalves, N. H. Silva, N. K. Honda, N. S, Santos-Magalhaes, J. Microencapsul. 21 (2004) 371 (

N. P. Santos, S. C. Nascimento, J. F. Silva, E. C. G. Pereira, N. H. Silva, N. K. Honda, N. S. Santos-Magalhaes, J. Drug Deliv. Sci. Tech. 15 (2005) 355 (

D. Venkataramana, D. R. Krishna, J. Chromatogr., B 575 (1992) 167 (

D. Venkataramana, D. R. Krishna, Eur. J. Drug Metab. Pharmacokin. 18 (1993) 161 (

X. Ji, I. A. Khan, J. AOAC Int. 88 (2005) 1265 PMID: 16385974 (

ICH: Harmonised tripartite guideline validation of analytical procedures: text and methodology Q2(R1), (assessed December 1, 2020)

ICH Q1A (R2) guideline. Stability testing of new drug substances and products, (assessed December 1, 2020)

M. P. Siqueira-Moura, M. C. B. Lira, N. S. Santos-Magalhaes, Braz. J. Pharm. Sci. 4 (2008) 622 (

European Pharmacopoeia (Ph. Eur. 10), Uniformity of content of single-dose preparations, Council of Europe, Strasbourg, 2020 (

Most read articles by the same author(s)